Directorate Change
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your NCYT notes
Paris, France, Eastleigh and Manchester, UK - 31 October 2024 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the appointment of Dr Ian Gilham as a Non-Executive Director with immediate effect. Dr Gilham will become a Board Director of the Company, subject to shareholder approval, at the Company's Annual General Meeting.
Ian has a wealth of experience in AIM-listed life sciences companies, with an international track record in the research, development and commercialisation of diagnostic products that will further strengthen the expertise of the Novacyt Board. He currently holds roles as Non-Executive Chairman of AIM-listed Genedrive PLC, Chair of Trustees for LifeArc, a self-funded medical research charity, Non-Executive Chairman of Pelago Bioscience AB, a life sciences tools business based in Stockholm and Non-Executive Chairman of RevoNA Bio, a University of Portsmouth spinout life sciences tools company. Ian has previously held Board positions at Aptamer Group PLC, Horizon Discovery PLC, Cytox Ltd, Elucigene Ltd, Multiplicom n.v, Biosufit s.a, Vernalis plc, Concepta Diagnostics Ltd and was CEO of Axis-Shield PLC.
Dr Ian Gilham, Non-Executive Director of Novacyt S.A.
Lyn Rees, CEO of Novacyt, commented: "It is a pleasure to welcome Ian to the Board of Novacyt. Ian has worked with a number of successful AIM-listed life sciences companies and we look forward to utilising his expertise as we further optimise and strengthen the Novacyt Group."
Additional Information
The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Ian David Gilham aged 64.
| Current Directorships / Partnerships | Former Directorships / Partnerships within the last 5 years |
| Genedrive Plc LifeArc Pelago Bioscience AB Revona Bio Ltd Stowheath Limited | Aptamer Group Plc BIOSURFIT s.a Cytox Limited Horizon Discovery Group Limited (Formerly Horizon Discovery Plc) Revvity Discovery Limited (Formerly Horizon Discovery Limited) |
On 4 January 2024, Cytox Limited, a company which Ian Gilham was previously a director of, appointed a liquidator in connection with a creditors voluntary winding up. No notice of administrators' proposal has yet been filed although the business was estimated to have a deficiency as regards creditors of £257,405.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.